07/12/2017 11:35:05

Travis Perkins PLC : Director/PDMR Shareholding

Related content
11 Dec - 
Travis Perkins PLC : Director/PDMR Shareholding
08 Dec - 
CORRECTION: Travis Perkins PLC - Director/PDMR Sharehol..
07 Dec - 
Travis Perkins PLC : Director/PDMR Shareholding

The Board of the Company was notified on 6 December 2017 of the exercise and sale of nil cost options under the Travis Perkins Listing Rule Buyout Scheme over the number of ordinary shares of 10p each in the Company by the PDMR as set out below:

Name Status No. of shares exercised Sale Date Number of Shares Sold Price Beneficial Interest % of ISC
Alan Williams PDMR 24,583 05/12/2017 11,578 £15.34 94,080 <0.1%

This Notification is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation, the Notification of Dealing Form for the PDMR can be found below.

Notification of Dealing Form

1

Details of the person discharging managerial responsibilities/ person closely associated 

a) Name Alan Williams

2

Reason for the notification

a) Position/Status Chief Financial Officer
b) Initial notification/Amendment Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer

or auction monitor

a) Name Travis Perkins plc
b) LEI 2138001I27OUBAF22K83

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)

each type of transaction; (iii) each date; and; (iv) each place where transaction have been

conducted

a) Description of the financial

instrument,

type of instrument

Identification code

Ordinary Shares of 10 pence each

 

 

ISIN: GB0007739609

b) Nature of the transaction Exercise and sale of options under the Travis Perkins Listing Rule Buyout Scheme
c) Price(s) and volume (s)    
Price(s) Volume(s)
£15.34 24,583
d) Aggregated information

 

 

-Aggregated volume

 

-Price

     
Aggregate

Price

Aggregate

Volume

Aggregate

Total

£15.34 24,583 £377,103.22
e) Date of the transaction 5 December 2017
f) Place of the transaction XLON

For Further information please contact:

Helen O'Keefe

Deputy Company Secretary

+44 (0)1604 685910


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Travis Perkins PLC via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Alliance Trust PLC : Transaction in Own Shares

15/12/2017 07:00:16
15 December 2017  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 14 December 2017 the Company purchased for cancellation 184,000 ordinary shares of 2.5p each at a price of 737.0383p per share.  Therefore, the total number of voting rights in the Company is now 347,592,156.    The above figure (347,592,156) may be used by sha..

Form 8.3 - Tesco PLC

14/12/2017 11:47:54
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Jupiter Asset Management (b) Owner or controlle..

Dimensional Fund Advisors Ltd. : Form 8.3 - Tesco Plc - Ordinary shares

14/12/2017 10:47:13
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Dimensional Fund Advisors Ltd. ("Dimensional"), in its capacity ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Voip-Pal.com, Inc. Discusses the Global Potential of its RBR Parent Patent
2
Make Christmas Personal with New Celebrity Video Ecards from American Greetings
3
Impac Mortgage Holdings, Inc. Announces Hire of Rian Furey to lead its Consumer Direct Retail Channel
4
Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae
5
Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae

Related stock quotes

Travis Perkins PLC ORD 1.. 1,520.00 0.0% Stock price unchanged

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
15 December 2017 08:17:05
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171124.1 - EUROWEB4 - 2017-12-15 09:17:05 - 2017-12-15 08:17:05 - 1000 - Website: OKAY